September 28, 2020

The Niche

Knoepfler lab stem cell blog

Labour and Welfare

2 min read

In a rare sign of stem cell international regulatory unity, the Japanese Health Ministry (厚生労働省) and the US FDA have agreed to develop a joint, unified regulatory framework for clinical studies of human iPS cells for use in treating retinal diseases. Presumably the rules would also guide clinical use of iPS cells to treat other diseases. The two regulatory bodies aim to have the joint rules in place by 2015. To me this seems like a positive development, but it may come a bit …Read More